NR1H4 and obesity due to melanocortin 4 receptor deficiency: Therefore, the control of the expression of bile acid receptors and the search for agonists and antagonists of these receptors provide conditions for the development of new pharmacological agents for the prevention and treatment of obesity, diabetes mellitus, and CVD [139].